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Abstract
Background: The emergence of  Enterobacteriaceae harboring IMP-4 or IMP-8 carbapenemases is rare. We report an occurrence of  En-
terobacteriaceae harboring IMP-4 or IMP-8 carbapenemases in a Chinese tertiary care hospital from November 2010 to December 2012.
Methods: The clinical characteristics of  30 patients were described. The genetic relationship of  isolates was determined by pulsed-field 
gel electrophoresis (PFGE). Carbapenemases were detected by modified Hodge test (MHT) and polymerase chain reactions (PCRs). 
Amplicons were sequenced and blasted to determine the genotype.
Results: Most infected patients were from intensive care unit and had complex and serious underlying illnesses requiring mechanical 
ventilation. PFGE revealed that Klebsiella pneumoniae showed two major PFGE types. Two Klebsiella oxytoca had an indistinguishable PFGE 
pattern, while four Enterobacter cloacae were different strains. The sequencing studies showed Enterobacteriaceae harboring IMP-4 or IMP-8 
carbapenemase in the 23 infected patients. The majority of  patients had infections with the carbapenemase-producing Enterobacteriaceae 
(CPE) strain, most were successfully treated with a range of  antibiotics and discharged.
Conclusion: It is important to maintain a high index of  suspicion to screen for carbapenemase-producing Enterobacteriaceae strains. Rapid 
identification of  these strains and implementation of  stringent procedures are the key to prevent major outbreaks in a hospital setting.
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Introduction
Since 2000, spread of  community-acquired enterobac-
terial isolates (Escherichia coli) that produce extended-
spectrum β-lactamases (ESBLs) capable of  hydrolyzing 
almost all cephalosporins except carbapenems has been 
reported worldwide1. Carbapenems have become anti-
microbial drugs of  last resort therefore it is important 
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to maintain the clinical efficacy of  these antibiotics. The 
frequent use of  carbapenems, however, combined with 
the transmissibility of  resistance determinants mediated 
by plasmids, transposons and gene cassettes, has con-
tributed to the increase of  carbapenem resistance by En-
terobacteriaceae2,3. In countries such as the United States, 
Israel,Germany and Greece, carbapenemase-producing 
Enterobacteriaceae (CPE) had emerged and the dissemina-
tion of  these multidrug-resistant pathogens had become a 
problem in clinical care of  patients and in public health4-7. 
Invasive infections with these organisms have been asso-
ciated with high rates of  morbidity and mortality, due to 
their resistance to most available antimicrobial agents8-10. 
Patients who are hospitalized for prolonged periods and 
those with severe underlying disease are at high risk of  
acquiring these types of  pathogens11.
The Ambler classification describes various classes of  
carbapenemases12. Klebsiella pneumoniae carbapenemases 
(KPC) belong to class A; they are increasingly prevalent 
in parts of  the United States, Israel and Greece and are 
also an emerging concern in Western Europe13. Class B 
metallo-beta-lactamases of  the types IMP (imipenemase) 
and VIM (Verona integron-encoded metallo-beta-lacta-
mase) are common in non-fermentative bacteria and have 
been recently recognized in Enterobacteriaceae worldwide13. 
Strains carrying the recently reported New Delhi metallo-
beta-lactamase1 (NDM-1), found throughout India, Paki-
stan and Bangladesh, have also been rapidly disseminated 
to Europe and across the globe14. OXA-type (oxacillin-
hydrolysing) carbapenemases (Class D) are widespread 
and have been detected primarily in Enterobacteriaceae 15.
CPE have been sporadically reported in China in recent 
years. In 2009, two cases of  pulmonary infection due 
to multidrug-resistant K. pneumoniae strains producing 
blaIMP-4 and armA, which contained intervening sequences 
highly related to those of  a Vibrio cholerae plasmid found 
in Hangzhou, China16. In 2010, a study to investigate the 
resistance mechanism of  49 Enterobacteriaceae isolates with 
decreased susceptibility to carbapenems collected at 16 
teaching hospitals in China,confirmed the production 
of  KPC-2, IMP-4 and IMP-8 carbapenemase17. In 2011, 
the first NDM-1 producing E. coli isolate was detected in 
Hong Kong18.Here we report the emergence of Enterobac-
teriaceae harboring IMP-4 or IMP-8 carbapenemases in a 
Chinese tertiary care hospital. This report describes the 
emergence, the infection control measures implemented, 




Liaocheng People's Hospital is a 3000-bed tertiary care 
hospital serving about 139,000 inpatients per year. It has a 
43-bed general Intensive Care Unit (ICU) including medi-
cal ICU and surgical ICU, a 35-bed Neonatal Intensive 
Care Unit (NICU), a 30-bed Pediatric Intensive Care Unit 
(PICU) and a single 30-bed ICU in the Brain Hospital. All 
ICUs are mainly dealing with critically ill patients. Patients 
who no longer need mechanical ventilation or are in a 
stable condition will be transferred to general wards from 
ICU. Before the occurrence described in this report, no 
screening for carbapenem-non-susceptible Enterobacteria-
ceae (CNSE) was performed in the ICUs.
Microbiological methods
The non-duplicate Enterobacteriaceae strains were isolated 
from Liaocheng People's Hospital between November 
2010 and December 2012. The strains were sorted and 
numbered in accordance with the isolates of  the time. 
All isolates were identified using standard conventional 
microbial methods. The strain identification and anti-
microbial susceptibility testing were performed using a 
Vitek 2 automated system (bioMérieux, France). Suscep-
tibilities were interpreted using the Clinical and Labora-
tory Standards Institute (CLSI) M100–S20 breakpoints19. 
If  the minimum inhibitory concentration (MIC) to er-
tapenem was elevated (MIC≥ 2µg/mL), further testing 
by the modified Hodge test (MHT) was performed as 
phenotypic confirmatory method in order to investigate 
the mechanism of  resistance.
 
Detection of  carbapenemases
The MHT was performed as previously described19. PCRs 
were performed for blaKPC, blaIMP, blaVIM, blaOXA-48 and 
blaNDM-1 genes as previously described
20-23. The amplicons 
were sequenced in Shanghai Sangon company, sequenc-
ing instruments and reagents were ABI-PRISM3730 and 
BigDyeterminator v3.1 respectively. Then the sequencing 
results blasted to NCBI databases (www.ncbi.nlm.nih.




The genotypes of  isolates harboring carbapenemase 
genes were determined by using PFGE analysis. Salmo-
nella Braenderup H9812 strain DNA was used as stan-
dard size markers. The genetic relationship of  the test 
strains was generated by the unweighted pair-group 
method (UPGMA). Isolates that exhibited a PFGE pro-
file with more than 80% similarity (pulsotype, PT) were 
considered as closely related strains.
Results
Epidemiological investigations
Thirty CNSE strains were mainly isolated from patients 
hospitalized in ICUs of  Liaocheng People's Hospital, 
which includes twenty cases in NICU, three cases in Brain 
Hospital ICU, one case in PICU and one case in surgical 
ICU. Other five cases were from other clinical depart-
ments. Twenty-two patients were neonatal (73.3%) and 
five patients were over 60 years old (16.7%). All patients 
suffered from severe underlying diseases and most pa-
tients were treated with invasive procedures. Almost all 
patients had pulmonary infection (n=28), only two pa-
tients had orthopedic wound infections. The patient′s 
characteristics are shown in Table 1.
Infection control measures
Before April 2011, there had been 10 patients infected 
with CNSE isolates (patients 1-10, Table 1). Due to the 
long time interval and lack of  experiences, they did not 
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draw the attention of  clinical departments and hospi-
tal infection administrators. Follow-up medical records 
showed that these isolates were mainly isolated from the 
Brain Hospital ICU (patients 1,6,7). In addition, two or-
thopedic patients (patients 2, 8) were transferred to our 
hospital after post-operative infection in other hospitals 
and their information in other hospitals before trans-
ferred to our hospital was not retrieved.






















Pneumonia Levofloxacin Alive 
2/ECL1 M/24 
years 























Pneumonia Imipenem Alive 
5/KPN3 M/ 
neonatal 
NICU Premature infant, MODS, 

























Pneumonia Levofloxacin Alive 
8/KOX1 F/54 
years 


























Pneumonia Meropenem Alive 
11/KPN6 M/ 
neonatal 




Pneumonia Imipenem, cefepime Alive 
12/KPN7 M/ 
neonatal 







Pneumonia Cefoperazone/sulbactam Alive 
13/KPN8 F/ 
neonatal 
NICU Premature infant,MODS, 










NICU Premature infant,MODS, 
















Pneumonia None Alive 
16/KPN11 M/ 
neonatal 
NICU Premature infant, MODS, 




































Pneumonia Amoxicillin/sulbactam Alive 
20/ECL4 F/2 
years 


























Pneumonia None Alive 
23/KPN17 F/ 
neonatal 
NICU Premature infant, HIE, 
NRF, MODS, CHD 
None Tracheal 
secretion 
Pneumonia Piperacillin/tazobactam Alive 
24/KPN18 M/ 
neonatal 











Pneumonia Meropenem Alive 
26/KPN20 M/ 
neonatal 




Pneumonia Ceftriaxone Alive 
27/KPN21 M/ 
neonatal 
NICU Premature infant, HIE None Tracheal 
secretion 
Pneumonia Meropenem, Ceftriaxone Alive 
28/KPN22 F/ 
neonatal 




Pneumonia None Alive 
29/KPN23 M/ 
neonatal 











Premature infant, HIE None Tracheal 
secretion 
Pneumonia Meropenem Alive 
a KPN, Klebsiella pneumoniae; ECL, Enterobacter cloacae; KOX, Klebsiella oxytoca. 
b M, male; F, female. 
c TBI, traumatic brain injury; MI, myocardial infarction; GCA, gastric cardiac adenocarcinoma; CHD, congenital heart disease; NRF, neonatal respiratory failure; RDS, 
respiratory distress syndrome; HIE, hypoxic-ischemic encephalopathy; ICH, intracerebral hemorrhage; RA, rheumatoid arthritis; IVH, intraventricular hemorrhage; CPR, 
cardiopulmonary resuscitation. 
d NICU, neonatal intensive care units; PICU, pediatric intensive care unit. 
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Until late April 2011, consecutive cases with invasive in-
fections for CNSE in the NICU (Patients 12-14) were 
detected, and the strains were all isolated from bronchial 
aspirate specimen. By PCRs and subsequent sequencing, 
blaIMP-4 genes were detected from most strains, and the 
isolated K. pneumoniae and Klebsiella oxytoca were clonally 
related. Positive control measures were implemented and 
health care workers were informed about CNSE by leaf-
lets and informative meetings. The outbreak control team 
was organized and extended infection control measures 
were implemented in our hospital with the support of  
hospital administrators. In our hospital, Positive control 
1 measures were immediately implemented at the time 
of  admission of  CPE-positive patients, to ensure that no 
patients came into contact with a case. All CPE-positive 
patients were isolated immediately after detection by con-
tact isolation, and the objective of  these measures was 
to prevent future patient-to-patient transmission and in-
cluded: 
(a) Isolating patients in single rooms or isolating cohorts 
with the same species and same resistance profile, flag-
ging the presence of  cases by displaying a specific poster 
or logo on the CPE-positive patients beds and in the part 
of  the ward where these patients were cohorted; 
(b) All ICU personnel, including cleaning staff  and physi-
cal therapists, were instructed about standard hygiene 
procedures such as appropriate hand hygiene, use of  
gloves and gowns by medical personnel during physical 
contact, and use of  masks by medical personnel when 
exposure to respiratory secretions was expected; 
(c) environmental sites were investigated for CPE con-
tamination. The environmental samples were taken from 
medical devices, personal computers, telephones, door 
handles, floors and various other surfaces. Environmental 
sampling demonstrated no CPE were detected.
Despite the introduction of  these measures, during the 
following three months, four more patients (patients 15-
18) were identified in the NICU, who were infected with 
pneumonia with CNSE. After mid-July, no other cases 
were detected during the following two months.
 However, on September 25, 2011 and October 19, 2011, 
two cases (patient 19, 20) infected with CNSE were de-
tected, and the resistance was similar to the previous 
strains. But these strains were confirmed producing IMP-
8 carbapenemase, then the same control measures were 
implemented. From December 5, 2011 to December 29, 
2011, nine cases (patient 21-29) infected CNSE led to an-
other larger outbreak. All strains were isolated from tra-
cheal secretions in the NICU, including a case detected in 
the neonatology department which was transferred from 
NICU. The outbreak control team drew up more strict 
control measures, more strict control measures – Posi-
tive control 2 was implemented for the key departments, 
including stopping the transfer of  CPE-positive patients 
to other units or hospitals until the case was discharged 
and obtaining targeted surveillance samples from all inpa-
tients and contact patients in kinds of  ICU for additional 
measures.
Since then, such strains have been under effective con-
trol and have not been detected in the NICU. Only one 
patient (patient 30) was detected in another neonatology 
department, and had been transferred from the NICU. 
The spatio-temporal description of  patients infected with 
CNSE is shown in Figure 1. 
Clinical outcomes
Although there was no specific antibiotic treatment pro-
gram, most patients were alive and discharged (n=28). 
Only two patients died of  causes unrelated to CNSE. The 
clinical outcomes of  patients are shown in Table 1.
 
Antimicrobial susceptibility testing
According to 2010 CLSI criteria19, these recommenda-
tions include performing a MHT on isolates resistant to 
at least one extended-spectrum cephalosporin and with 
carbapenem MICs at the upper end of  the susceptible 
range (MICs of  2 to 4 μg/ml for imipenem or merope-
nem or 2 μg/ml for ertapenem), as they may produce car-
bapenemases. If  the MHT is negative, carbapenem MICs 
are to be reported as indicating susceptibility; if  the MHT 
is positive, carbapenem MICs are to be reported without 
an interpretation and with the following comment. “This 
isolate demonstrates carbapenemase production. The 
clinical efficacy of  the carbapenems has not been estab-
lished for treating infections caused by Enterobacteriaceae 
that test carbapenem susceptible but demonstrate car-
bapenemase production in vitro.”  The strains exhibited 
the same multidrug-resistant profile, all strains demon-
strated insensitivity to ertapenem and 18 strains showed 
elevated MIC to imipenem (accounted for 60%). 
Most strains exhibited resistance to cephalosporins and 
sulfonamides, the resistance rates to ceftriaxone, ceftazi-
dime, cefepime and trimethoprim/sulfamethoxazole were 
100%, 100%, 80% and 93.3% respectively. However, the 
isolates showed sensitivity to aminoglycosides, fluoroqui-
nolones and beta-lactamase inhibitor combination, the 
resistance rates to gentamicin, tobramycin, ciprofloxacin 
and piperacillin/tazobactam were 56.7%, 16.7%, 13.3% 
and 20% respectively. No full resistance to tigecycline 
and polymyxin B was observed among the tested strains 
(Table 2).
Carbapenemase characterisation
All isolates were screened for carbapenemase produc-
tion using phenotypic and molecular methods. The MHT 
yielded positive results in 25 of  the 30 isolates, including 
23K. pneumoniae (KPN1-KPN3, KPN5-KPN24), one 
strain of  Enterobacter cloacae (ECL4) and one strain of  K. 
oxytoca (KOX2), indicating the presence of  a carbapen-
emase. 
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Fig 1. Spatio-temporal description of patients infected with carbapenem-non-susceptible Enterobacteriaceae (n=30)
By PCRs and subsequent sequencing, blaIMP-4 genes were 
detected in 11 strains isolated from the patients be-
fore May 2011, while isolates from twelve patients had 
blaIMP-8 genes detected. No blaKPC, blaVIM, blaOXA
-48, and 
blaNDM
-1 genes were amplified positive in all strains (Table 
2).
Nucleotide sequence accession number
The sequence of  the blaIMP-4-containing plasmid in K. 
pneumoniae was submitted to GenBank under accession 
no. JQ808503, the blaIMP-4-containing plasmid in K. oxy-
toca under accession no. JQ820404. And the sequence of  
the blaIMP-8-containing plasmid in K. pneumoniae was sub-
mitted to GenBank under accession no. JQ820405, the 
blaIMP-8-containing plasmid in E. cloacae under accession 
no. JQ820406.
Phylogenetic analysis
PFGE of  24 K. pneumoniae isolates identified 6 pulsotypes, 
pulsotype (PT) PT1 to PT6 using 80% similarity as the 
cut-off. PT1 and PT2 were the major cluster, included 
8isolates (KPN2, KPN3, KPN5, KPN7, KPN8, KPN10-
KPN12) and 12 isolates (KPN13-KPN24) respectively. 
PT3-6 included the other 4 isolates (KPN1, KPN4, 
KPN6 KPN9). PFGE revealed that two K. oxytoca had 
an indistinguishable PFGE pattern, while four E. cloacae 
were different strains.
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KPN1 + blaIMP-4 4 8 ≤1 ≤1 8 ≥64 ≥64 32 ≤0.25 ≥320 
KPN2 + blaIMP-4 ≥8 2 ≥16 8 64 ≥64 ≥64 ≥64 2 ≥320 
KPN3 + blaIMP-4 4 ≤1 ≥16 8 8 ≥64 ≥64 ≥64 1 ≥320 
KPN4 - None 4 2 ≥16 8 8 ≥64 ≥64 32 1 ≥320 
KPN5 + blaIMP-4 4 ≤1 ≥16 8 8 ≥64 ≥64 8 0.5 ≥320 
KPN6 + None 4 8 4 8 8 ≥64 ≥64 ≥64 ≤0.25 ≥320 
KPN7 + blaIMP-4 ≥8 ≤1 ≥16 8 64 ≥64 ≥64 16 2 ≥320 
KPN8 + blaIMP-4 4 ≤1 ≥16 8 32 ≥64 ≥64 ≥64 2 ≥320 
KPN9 + None 4 ≤1 ≥16 8 16 ≥64 ≥64 ≥64 2 ≥320 
KPN1
0 + blaIMP-4 ≥8 ≤1 ≥16 8 8 ≥64 ≥64 8 1 ≥320 
KPN1
1 + blaIMP-4 4 ≤1 ≥16 8 8 ≥64 ≥64 8 2 ≥320 
KPN1
2 + blaIMP-4 4 2 ≥16 8 8 ≥64 ≥64 ≥64 2 ≥320 
KPN1
3 + None 4 ≤1 ≥16 8 8 ≥64 ≥64 8 1 ≥320 
KPN1
4 + blaIMP-8 4 ≤1 ≥16 8 ≥128 ≥64 ≥64 ≥64 1 ≥320 
KPN1
5 + blaIMP-8 4 4 2 8 8 ≥64 ≥64 ≥64 ≤0.25 ≥320 
KPN1
6 + blaIMP-8 4 4 4 8 8 ≥64 ≥64 ≥64 ≤0.25 ≥320 
KPN1
7 + blaIMP-8 4 4 4 8 8 ≥64 ≥64 ≥64 ≤0.25 ≥320 
KPN1
8 + blaIMP-8 4 4 4 8 8 ≥64 ≥64 ≥64 ≤0.25 ≥320 
KPN1
9 + blaIMP-8 4 2 4 8 8 ≥64 ≥64 ≥64 ≤0.25 ≥320 
KPN2
0 + blaIMP-8 4 4 4 8 8 ≥64 ≥64 ≥64 ≤0.25 ≥320 
KPN2
1 + blaIMP-8 4 8 4 8 8 ≥64 ≥64 ≥64 ≤0.25 ≥320 
KPN2
2 + blaIMP-8 4 4 4 8 8 ≥64 ≥64 ≥64 ≤0.25 ≥320 
KPN2
3 + blaIMP-8 4 4 4 8 8 ≥64 ≥64 ≥64 ≤0.25 ≥320 
KPN2
4 + blaIMP-8 4 2 ≤1 8 8 ≥64 ≥64 16 ≤0.25 ≥320 
ECL1 - None 4 ≤1 ≥16 ≥16 ≥128 ≥64 ≥64 ≥64 ≥4 ≥320 
ECL2 - None 4 ≤1 ≥16 ≥16 ≥128 ≥64 ≥64 ≥64 ≥4 ≤20 
ECL3 - None 4 ≤1 ≥16 ≥16 ≥128 ≥64 ≥64 ≥64 0.5 ≤20 
ECL4 + blaIMP-8 ≥8 4 ≤1 ≤1 8 ≥64 ≥64 32 ≤0.25 ≥320 
KOX
1 - blaIMP-4 ≥8 8 ≥16 ≥16 ≥128 ≥64 ≥64 ≥64 ≥4 80 
KOX
2 + blaIMP-4 ≥8 ≥16 ≥16 ≥16 ≥128 ≥64 ≥64 ≥64 ≥4 ≥320 
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Discussion
The emergence of  Enterobacteriaceae harboring IMP-4 or 
IMP-8 carbapenemases described in this report faced 
two different outbreaks in a tertiary hospital in China. Al-
though cases from other cities in China have been report-
ed, all of  these reports were individually IMP-4 or IMP-8 
genotype, and the number of  cases were small16,24-28. This 
occurrence included a variety of  Enterobacteriaceae, which 
was mainly K. pneumoniae. Two kinds of  PEGF types that 
presented by K. pneumoniae originated in the NICU, which 
could have been the source of  such strains. Infection con-
trol departments were focused on monitoring the depart-
ments during the occurrence, and had achieved signifi-
cant results. Together with the indistinguishable PFGE 
pattern, this strongly suggests that this mechanical venti-
lation represented a persistent source of  contamination. 
The source of  the IMP-producing K. oxytoca could not be 
fully elucidated, although the facts suggest that the PFGE 
pattern was closely related. Because the two patients were 
transferred to our hospital after post-operative infection 
in other hospitals. Four E. cloacae had a long separation 
time interval, and PFGE proved to be a different pattern, 
the source was not easy to determine.
The main characteristics of  this occurrence are that pa-
tients were mainly from ICU and had suffered from se-
vere underlying diseases which were treated with invasive 
procedure. Patients suffering from severe underlying dis-
ease are routinely and extensively given broad-spectrum 
anti-infective agents as prophylaxis or targeted therapy. 
Broad-spectrum antibiotic therapy exerts a selective pres-
sure towards resistant organisms and affects the normal 
body flora. Furthermore, intensive care medicine, includ-
ing use of  medical devices, allows pathogens to colonize 
or infect patients. 
In an outbreak described by Yan et al.24, sixteen patients 
were detected to carry blaIMP-8 and all infections were 
nosocomially acquired. The organisms caused wound in-
fections in eight patients and bloodstream infections in 
three patients. They were not directly associated with the 
death of  nine patients24. The outcome of  our patients 
seemed to be better compared to the previously reported 
data. As the isolates were broadly resistant to most anti-
biotic classes, various combination therapies were used 
with little effect according to the in vitro susceptibility re-
sults. Fortunately, most patients were successfully treated 
with quinolones guided by the antimicrobial susceptibil-
ity, and the other patients were also successfully treated 
with broad-spectrum cephalosporins and carbapenem in 
spite of  no reliable in vitro activity. Maybe it could be ex-
plained based on principles of  PK/PD and clinical data, 
appropriate drainage in surgical and prompt removal of  
ventilator in NICU lifted the source of  bacterial infec-
tion effectively. The favorable clinical outcomes experi-
enced by the patients treated with beta-lactam antibiotics 
have been previously reported29, but the degree to which 
the antibiotic treatment contributed to these outcomes is 
difficult to ascertain. In the United States, three K. pneu-
moniae harboring IMP-4 carbapenemase were recovered 
from pediatric patients, and these isolates had a similar re-
sistance with our strains30. Good clinical response to an-
tibiotics with no in vitro activity might have been achieved 
by the increased antimicrobial concentration.
MHT is CLSI recommended method to detect carbape-
nem of  Enterobacteriaceae, and has a good sensitivity and 
specificity to detect KPC but still uncertain to Ambler B 
metals enzyme19. Doyle et al.31 reported that MHT had a 
good effect to detect KPC and OXA-48 carbapenemase, 
but was insufficient to the metal enzyme IMP, VIM and 
NDM-1. Our study demonstrated that MHT had a high 
sensitivity to detect IMP-4- or IMP-8-type carbapen-
emase, that confirmed MHT can effectively detect En-
terobacteriaceae producing IMP-type carbapenemases. The 
false-positive results of  MHT of  the CPE isolates may 
be attributed to the high level AmpC or ESBLs enzymes 
producers combined with loss or decreased expression 
of  major porins32. It should be noted that early detection 
of  carbapenem resistant isolates is of  utmost importance 
in allowing adequate antimicrobial therapy to be initiated 
and in avoiding cross-transmission. Thus, suspicion must 
be high in multi-resistant enterobacterial isolates with el-
evated MICs to ertapenem. MICs derived by the Vitek 2 
system were usually comparably low for imipenem and 
meropenem, whereas testing with microbroth dilution re-
vealed higher MICs. This problem has been reported pre-
viously33. However, the Vitek 2 system is widely used in 
Chinese laboratories, and if  included in the testing panel 
such as AST-GN13, ertapenem may serve as an indicator 
for the detection of  IMP carbapenemase. A study recom-
mended using molecular tests for the optimal detection 
of  carbapenemase-producing Enterobacteriaceae31. When 
obtaining the possibility of  CPE strains, they should be 
promptly examined by PCR to confirm the genotype.
IMP-type metalloenzymes have been reported world-
wide, with a higher prevalence in southern Europe and 
Asia. The first acquired MBL, IMP-1, was reported in Ser-
ratia marcescens in Japan in 199134. Since then, IMP-type 
enzymes has been described worldwide, and endemic-
ity of  IMP-type enzymes has been reported in in many 
countries35. However, Most MBL producers are hospital 
acquired and multidrug-resistant K. pneumoniae36. The first 
metallo-β-lactamase reported from China was IMP-4, 
which was detected on a plasmid in C.youngae and report-
ed in a 2001 publication36, followed by reports of  IMP-1 
and IMP-9 in a P. aeruginosa isolate37,38. 
In an outbreak described by Peleg et al.39, five different 
gram-negative genera from patients with close epidemio-
logical links were involved. It showed blaIMP-4 appearing 
highly mobile in different gram-negative strains, which 
brought greater challenges to infection control. Addi-
tional cross-transmission was then prevented by strict 
patient isolation, intensified hand disinfection and the 
routine analysis of  targeted surveillance cultures. Preven-
tive contact precautions should be carried out for such 
patients until the negative results of  microbiology studies 
have been obtained. Although we may have terminated 
the outbreak in our institution, the high number of  con-
tact patients that resulted from long hospitalisation times 
and frequent transferring of  the highly care-dependant 
patients makes it unlikely that the establishment of  IMP 
in China could be prevented.African Health Sciences Vol 16 Issue 1, March 2016  159
Conclusion
CPE harboring IMP-4 or IMP-8 carbapenemase strains 
had emerged in our hospital. Rapid dissemination of  
CPE was a serious concern in clinical patient care and 
these pathogens were now also present in China. There-
fore, using surveillance cultures and initiating strict hy-
giene procedures is mandatory for the prevention and 
early detection of  carbapenem-resistant Enterobacteriaceae 
in units where high-risk patients receive care.
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